Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 5.66
+0.23 (4.24%)
May 11, 2026, 4:08 PM HKT
Sino Biopharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 2,343 | 3,500 | 2,332 | 2,544 | 14,608 |
Depreciation & Amortization | 1,041 | 1,175 | 1,004 | 967.54 | 922.74 |
Other Amortization | 170.1 | 145.7 | 70.05 | 79.45 | 129.82 |
Loss (Gain) From Sale of Assets | -11.17 | -116.22 | -62.69 | -3.47 | 4.28 |
Asset Writedown & Restructuring Costs | 71.92 | 305.43 | - | 19.4 | 492.1 |
Loss (Gain) From Sale of Investments | 1,548 | 1,483 | 13.72 | 449.08 | 420.04 |
Loss (Gain) on Equity Investments | 151.38 | 118.3 | 525.71 | 152.98 | -13,631 |
Stock-Based Compensation | 115.97 | 53.72 | 18.12 | 29.72 | - |
Provision & Write-off of Bad Debts | 16.19 | 12.79 | -12.26 | 3.93 | 1.62 |
Other Operating Activities | 881.99 | -257.16 | 2,316 | 1,655 | 2,757 |
Change in Accounts Receivable | 615.19 | -413.99 | -816.03 | -421.66 | -1,308 |
Change in Inventory | 116.48 | -273.06 | 135.32 | -391.1 | -57.48 |
Change in Accounts Payable | -701.92 | 130.11 | 284.3 | -55.8 | -257.84 |
Change in Unearned Revenue | 63.95 | 29.26 | -142.32 | 74.62 | 66.25 |
Change in Other Net Operating Assets | 2,869 | 714.15 | 108.21 | 598.34 | 1,218 |
Operating Cash Flow | 9,292 | 6,615 | 6,066 | 6,265 | 5,366 |
Operating Cash Flow Growth | 40.46% | 9.06% | -3.18% | 16.75% | 0.77% |
Capital Expenditures | -1,239 | -960.1 | -1,068 | -1,243 | -1,714 |
Sale of Property, Plant & Equipment | 48.73 | 70.85 | 100.99 | 27.89 | 132.2 |
Cash Acquisitions | -5,022 | 2.66 | -1,157 | - | -798.75 |
Divestitures | 346.83 | 1,404 | 413.81 | -146.17 | - |
Sale (Purchase) of Intangibles | -464.16 | -434.06 | -406.78 | -302.94 | -152.92 |
Investment in Securities | -7,975 | -3,819 | 568.91 | -3,703 | -4,391 |
Other Investing Activities | 1,891 | 2,026 | 790.43 | 1,297 | 4,408 |
Investing Cash Flow | -12,414 | -1,709 | -756.98 | -4,071 | -2,516 |
Short-Term Debt Issued | - | - | - | - | 136.13 |
Long-Term Debt Issued | 13,601 | 11,696 | 12,194 | 9,753 | 1,270 |
Total Debt Issued | 13,601 | 11,696 | 12,194 | 9,753 | 1,406 |
Long-Term Debt Repaid | -7,257 | -14,475 | -13,948 | -8,790 | -2,908 |
Net Debt Issued (Repaid) | 6,344 | -2,779 | -1,754 | 962.99 | -1,501 |
Repurchase of Common Stock | -110 | -1,252 | -396.39 | -867.61 | -332.93 |
Common Dividends Paid | -1,503 | -1,846 | -632.67 | -1,268 | -938.49 |
Other Financing Activities | -573.66 | -437.24 | -3,766 | -2,014 | -452.37 |
Financing Cash Flow | 4,157 | -6,315 | -6,549 | -3,186 | -3,225 |
Foreign Exchange Rate Adjustments | 118.07 | 135.52 | 90.52 | 47.32 | -649.71 |
Net Cash Flow | 1,153 | -1,274 | -1,150 | -944.73 | -1,025 |
Free Cash Flow | 8,053 | 5,655 | 4,998 | 5,022 | 3,652 |
Free Cash Flow Growth | 42.41% | 13.15% | -0.48% | 37.50% | -6.38% |
Free Cash Flow Margin | 25.30% | 19.59% | 19.08% | 19.30% | 13.60% |
Free Cash Flow Per Share | 0.45 | 0.31 | 0.27 | 0.26 | 0.19 |
Cash Interest Paid | 273.91 | 287.25 | 480.83 | 339.52 | 179.62 |
Cash Income Tax Paid | 1,604 | 1,001 | 746.57 | 892.09 | 726.72 |
Levered Free Cash Flow | 6,601 | 3,905 | 3,006 | 2,991 | -196.74 |
Unlevered Free Cash Flow | 6,775 | 4,089 | 3,316 | 3,259 | -3.85 |
Change in Working Capital | 2,963 | 186.47 | -430.51 | -195.6 | -339.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.